Aβ42, t-Tau, p-Tau, α-syn and DJ-1 were decreased in early clinical PD patients compared to the controls (unadjusted p = 0.002, p = 0.033, p = 0.021, p = 0.015, p = 0.022, p = 0.002, respectively), whereas S100β levels was increased in early clinical PD patients (p = 0.025) (Fig 2A–2F). This evidence concerns the gene S100B and Parkinson disease.